These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 36193794)

  • 1. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.
    Zheng J; Wang Y; Hu C; Zhu M; Ii J; Lin C; Lu C; Dou Y; Zhao C; Zhang Y; Wu D; Li L; Tang H; He T; Pan C; Han R; He Y
    Thorac Cancer; 2022 Nov; 13(22):3162-3173. PubMed ID: 36193794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.
    Li Y; Xu Z; Wang S; Zhu Y; Ma D; Mu Y; Ying J; Li J; Xing P
    Thorac Cancer; 2022 Aug; 13(15):2201-2209. PubMed ID: 35778830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.
    Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM
    Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients.
    Chiou CC; Wang CL; Luo JD; Liu CY; Ko HW; Yang CT
    Cancer Genomics Proteomics; 2020; 17(4):417-423. PubMed ID: 32576586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
    Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K
    Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
    Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
    Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
    Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
    Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
    Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.
    Tran HT; Lam VK; Elamin YY; Hong L; Colen R; Elshafeey NA; Hassan ISA; Altan M; Blumenschein GR; Rinsurongkawong W; Rivera MJ; Vasquez ME; Carter BW; Byers LE; Tsao AS; Gibbons DL; Fossella F; Glisson BS; Zhang J; Heymach JV
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34377884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
    Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
    Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
    Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
    Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).
    Mack PC; Miao J; Redman MW; Moon J; Goldberg SB; Herbst RS; Melnick MA; Walther Z; Hirsch FR; Politi K; Kelly K; Gandara DR
    Clin Cancer Res; 2022 Sep; 28(17):3752-3760. PubMed ID: 35713632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Huang KT; Chen HC; Chang YC; Lin MC
    Medicine (Baltimore); 2015 Dec; 94(50):e2239. PubMed ID: 26683939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
    Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
    Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma.
    Lee JY; Jeon S; Jun HR; Sung CO; Jang SJ; Choi CM; Chun SM
    Cancer Res Treat; 2024 Apr; 56(2):484-501. PubMed ID: 37871897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.